“Ovarian Cancer Australia was my safe place when I was diagnosed. It is a wonderful organisation — full of information to help you, full of people who do not judge you, full of people going through or who have been through what you are going through. Lean on them for help.”
Meghan, ovarian cancer survivor
# TABLE OF CONTENTS

<table>
<thead>
<tr>
<th>Section</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>A MESSAGE FROM THE CHAIR &amp; CHIEF OPERATING OFFICER OF OVARIAN CANCER AUSTRALIA</td>
<td>4</td>
</tr>
<tr>
<td>ABOUT OVARIAN CANCER AUSTRALIA</td>
<td>6</td>
</tr>
<tr>
<td>THE IMPACT OF OVARIAN CANCER IN AUSTRALIA</td>
<td>7</td>
</tr>
<tr>
<td>OVARIAN CANCER AUSTRALIA’S AWARENESS PROGRAMS</td>
<td>8</td>
</tr>
<tr>
<td>OVARIAN CANCER AUSTRALIA’S SUPPORT PROGRAMS</td>
<td>9</td>
</tr>
<tr>
<td>OVARIAN CANCER AUSTRALIA’S ADVOCACY WORK</td>
<td>11</td>
</tr>
<tr>
<td>OVARIAN CANCER AUSTRALIA’S RESEARCH PROGRAM</td>
<td>12</td>
</tr>
<tr>
<td>2012 OVARIAN CANCER AWARENESS MONTH</td>
<td>13</td>
</tr>
<tr>
<td>OUR PARTNER ACTIVITIES</td>
<td>17</td>
</tr>
<tr>
<td>VOLUNTEER FUNDRAISING ACTIVITIES</td>
<td>19</td>
</tr>
<tr>
<td>SPONSORS</td>
<td>21</td>
</tr>
<tr>
<td>2011-12 FINANCIAL REPORT</td>
<td>25</td>
</tr>
</tbody>
</table>
In Ovarian Cancer Australia’s 10th year of operation the organisation has achieved more than ever.

In July 2011 we celebrated our 10th anniversary in style. It was wonderful to look back on the last decade and to acknowledge all the people and organisations that have helped to make us what we are today and we very much appreciate their support and dedication to our cause. It was also very exciting to announce at our anniversary event the launch of Ovarian Cancer Australia’s new research program: the first ever national peer-reviewed research program for ovarian cancer focussed on early detection, diagnosis and treatment. Our research program is guided by a research committee of experts and we are delighted that the CEO of Cancer Council Australia, Professor Ian Olver, has taken on the role of Chair of the Research Committee. Ovarian Cancer Australia looks forward to awarding our first grants in late 2012 to the brightest Australian PhD students undertaking further studies in ovarian cancer research.

Whilst we are excited to be entering the research space, Ovarian Cancer Australia remains firmly dedicated to our awareness programs to raise awareness of ovarian cancer and its symptoms in the community; and to our support programs for women diagnosed and their families. This year we published the new edition of our flagship resource, Resilience, a personal guide and record for women with ovarian cancer. We celebrated this achievement on Teal Ribbon Day with an event co-convened with Cancer Australia at Parliament House in Canberra and attended by the Federal Minister for Health, the Hon. Tanya Plibersek who formally launched Resilience. Our Ovarian Cancer Awareness Month continues to build momentum and each year we raise even greater awareness of the symptoms of ovarian cancer and its impact on women diagnosed and their families.

Over the past year I am particularly proud of the partnerships we have forged with other cancer and support organisations. As well as building on our partnerships with the Victorian Government and Cancer Australia it was an honour to be invited to co-host a consumer research forum with Prostate Cancer Foundation of Australia and to attend the Cancer Research Leadership Forum. We have also enjoyed working with BreaCan on a joint project in Victoria and we look forward to launching a national collaborative project led by Cancer Council Victoria later in 2012.

We are very grateful to our wonderful corporate and community supporters over the past 12 months and we look forward to our continued shared success in the coming year.

Our research program heralds a new and exciting chapter in Ovarian Cancer Australia’s history and with the addition of ovarian cancer research to our awareness, support and advocacy programs we know we can make an even greater difference.

Paula Benson
Chair
The past 12 months have been an eventful time for Ovarian Cancer Australia. From our 10th anniversary event in July 2011 to opening applications for our new research program in May 2012, it has been a year of reflecting on what we have achieved and looking forward to exciting new initiatives and challenges.

As well as maintaining our existing awareness and support programs, we have been working on a number of new projects. The revised edition of *Resilience* was a key achievement; and our joint project with BreaCan to improve access to information and support for women in Victoria with a gynaecological cancer has created new connections with women diagnosed and the health sector and provided useful insights into women’s support needs which will inform our programs nationally.

In 2011-12 we welcomed a new Support Coordinator in Sydney and a Support Coordinator in Perth. They have been instrumental in raising the organisation’s profile in NSW and Western Australia and providing information about Ovarian Cancer Australia’s services and resources to health professionals and women diagnosed with ovarian cancer.

Some of our innovative new awareness activities include a Symptom Diary mobile application with funding from the Victorian Government Department of Health and a new Community Service Announcement for television, both of which we will launch in the coming months.

Ovarian Cancer Awareness Month in February was again an extremely busy and rewarding month. Events and activities were held right across the nation and we were delighted to see our fundraising and awareness initiative, ‘Afternoon Teal’, grow in popularity and our new awareness message K.I.S.S. (Know the Important Signs & Symptoms), which we launched on Valentine’s Day, capture so much attention in print, online and social media. A huge thank you to our wonderful Ambassadors who played an important role in generating media coverage and to the women who bravely shared their stories.

Thank you also to our fabulous fundraisers and volunteers for their energy and support, and to the board and team of Ovarian Cancer Australia for their ongoing passion and commitment. We look forward to working together in the year ahead.

**Annabel Davies**  
Chief Operating Officer
ABOUT OVARIAN CANCER AUSTRALIA

Ovarian Cancer Australia is the country’s only national not-for-profit organisation dedicated to raising awareness of ovarian cancer, delivering support to women and their families affected by the disease, and funding the best ovarian cancer research.

Ovarian Cancer Australia’s Vision is to ensure that:
Every Australian woman knows the symptoms of ovarian cancer and everyone affected by ovarian cancer feels personally supported and has access to and information about the best treatment and research.

Ovarian Cancer Australia’s Mission is to:
Support women with ovarian cancer, their families, friends and carers with compassionate support programs and practical resources.

Educate communities and individuals about the disease and increase their awareness of symptoms and the latest treatment, research and clinical trials from across Australia.

Advocate to improve outcomes, treatment and quality of life for women with ovarian cancer.

Fund innovative and world leading ovarian cancer research.

Our Values are:
• Friendship – we know that working together is how we can make a difference.
• Respect – we welcome diverse opinions and listen to others.
• Courage – we are confident and we speak out.
• Integrity – we believe that good governance and evidence-based medicine are vital.
• Optimism – we have hope for the future.

Ovarian Cancer Australia is a key part of an international alliance of ovarian cancer organisations that work to raise awareness of ovarian cancer on a global scale including:
• Ovarian Cancer Action (UK) and Ovacome (UK)
• Ovarian Cancer National Alliance (USA)
• Ovarian Cancer Canada
• New Zealand Gynaecological Cancer Foundation

WHO WE ARE

PATRON
Nicole Livingstone OAM

BOARD
Chair
Paula Benson
Founding Director
Karen Livingstone
Founding Director
Simon Lee
Director
Carolyn Reynolds
Director
Stephanie Alvarez

STAFF
Chief Operating Officer
Annabel Davies
Support Programs Manager
Nicole Wilton
Support Programs Officer (part-time)
Rebecca Steele
Community Relations Officer
Helen Malley
Regional Support Coordinator (part-time)
Roxanne Kirk
Sydney Support Coordinator (part-time)
Helen Gooden
Perth Support Coordinator (part-time)
Angela Rowe
Administration Officer
Karen-Ann Leslie / Katrina Love
THE IMPACT OF OVARIAN CANCER IN AUSTRALIA

In Australia, 1 in 79 women will develop ovarian cancer by the age of 85.

Each year, around 1300 Australian women are diagnosed with ovarian cancer and more than 800 will die from the disease. On average 3 Australian women are diagnosed every day.

Approximately 75% of women are diagnosed at an advanced stage, where the cancer has spread and is very difficult to treat successfully. More than half these women will not live beyond the benchmark five years after their diagnosis.

But if ovarian cancer is diagnosed at an early stage, women have an 80% chance of being alive and well after five years.

The four most commonly reported symptoms by women with ovarian cancer are:

- Abdominal or pelvic pain.
- Increased abdominal size or persistent abdominal bloating.
- Needing to urinate often or urgently.
- Difficulty eating or feeling full quickly.

Other symptoms can include:

- Changes in bowel habits.
- Bleeding in-between periods or after menopause.
- Back pain.
- Unexplained weight gain or weight loss.
- Indigestion or nausea.
- Excessive fatigue.
- Pain during intercourse.

There is currently no reliable early detection test or screening program for ovarian cancer and the Pap test does not detect ovarian cancer. That is why every woman needs to know the symptoms of ovarian cancer.

Many women will experience symptoms from time to time, and they are often associated with less serious and more common health problems. But if these symptoms are new and have persisted for more than 12 days during a 4-week period, women should make an appointment to see their doctor.

Ovarian Cancer Australia works with a Medical & Research Advisory Group of leading gynaecological and medical oncologists, oncology nurses and researchers from across Australia who provide expert advice and input into our programs and resources. This group includes:

**Professor David Bowtell**  
Head, Cancer Genomics and Genetics, PI Australian Ovarian Cancer Study, Peter MacCallum Cancer Centre

**Karen Campbell**  
Cancer Care Coordinator, Gynaecologic Oncology Royal Hobart Hospital, Tasmania

**Professor Michael Friedlander**  
Professor of Medicine, University of NSW and Director of Medical Oncology, Prince of Wales Hospital, Sydney

**Dr Gregory Gard**  
Gynaecological Oncologist, Royal North Shore Hospital, Sydney

**Professor Neville F. Hacker**  
Professor of Gynaecological Oncology, Conjoint, University of New South Wales

**Dr Orla McNally**  
Consultant Gynaecological Oncologist, Royal Women’s Hospital, Melbourne

**Dr Linda Mileshkin**  
Consultant Medical Oncologist, Peter MacCallum Cancer Centre and Mercy Hospital for Women, Melbourne

**Dr Gillian Mitchell**  
Practicing Clinical Oncologist and Director, Familial Cancer Centre, Peter MacCallum Cancer Centre

**Dr Deborah Neesham**  
Gynaecological Oncologist, Royal Women’s Hospital, Melbourne

**Professor Andreas Obermair**  
Queensland Centre for Gynaecological Cancer, University of Queensland – Medical School

**Associate Professor Lewis C. Perrin**  
Clinical Director, Mater Gynaecological Oncology Service, Queensland

**Professor Michael Quinn**  
Department of Obstetrics and Gynaecology, University of Melbourne, Consultant Oncology/Dysplasia Unit, Royal Women’s Hospital, Melbourne

**Dr Stuart Salfinger**  
Gynaecologic Oncologist, King Edward Memorial Hospital, Perth

**Pauline Tanner**  
Gynaecology Cancer Nurse Coordinator, WA Cancer and Palliative Care Network – Health Department of WA

**Dr Helen Zorbas**  
CEO, Cancer Australia
In 2011-12 Ovarian Cancer Australia’s key awareness programs and resources include:

- **Ovarian Cancer Awareness Month and Teal Ribbon Day** – Held each year in February, Awareness Month includes a national media campaign, celebrity ambassadors and community activities around the country to raise awareness of ovarian cancer and funds for Ovarian Cancer Australia’s programs. On Teal Ribbon Day, we invite all Australians to purchase and wear a Teal Ribbon to demonstrate their commitment to raising awareness of ovarian cancer. For the highlights of 2012 Ovarian Cancer Awareness Month please turn to page 13.

- **A comprehensive website** – Ovarian Cancer Australia’s website is designed to be a hub of information about ovarian cancer. It is dedicated to raising awareness of the disease and providing information and support options for women diagnosed and their families. In 2011-12, 155,000 people visited our website.

- **A Community Ambassador program** – Over the past year our volunteer Community Ambassadors have been raising awareness of ovarian cancer in their local communities by hosting talks and presentations. A very special thank you to all of our dedicated Community Ambassadors: Helen Clark, Sally Whitford, Dorinda Leeder, Noala Flynn, Sarah Madacki, Victoria Jayde, Jane Tracey and Cindy Jeong.

- **A Symptom diary** – A useful and easy-to-use paper-based tool for women to track symptoms and better communicate what they are experiencing to their doctor.

- **Awareness brochures and posters** – With information about the symptoms and risks of ovarian cancer, thousands of our brochures and posters are distributed free of charge to individuals, businesses and community groups around the country throughout the year.
Ovarian Cancer Australia provides a range of support services for everyone affected by ovarian cancer. Our support and awareness resources are informed by a Medical & Research Advisory Group of leading gynaecological oncologists as well as scientific and medical professionals from across Australia (see page 6 for details) to ensure they meet the needs of women diagnosed with ovarian cancer.

In 2011-12 Ovarian Cancer Australia’s new support initiatives include:

**Resilience, new edition** – In February Ovarian Cancer Australia launched a new edition of our flagship resource, *Resilience*, a free guide and personal record for women diagnosed with ovarian cancer. The guide includes information on diagnosis, treatment, well-being, support for women, their carers and families as well as useful, practical information. The new edition was created with the input and feedback of women diagnosed with ovarian cancer and our Medical & Research Advisory Group. We are very grateful to all the women and their families who contributed inspiring and insightful quotations for the resource and took part in our photo day.

Ovarian Cancer Australia launched the new edition of *Resilience* at an event co-convened with Cancer Australia at Parliament House in Canberra on Teal Ribbon Day. The theme of the event was ‘Supporting the emotional and psychological needs of women with ovarian and gynaecological cancers’. Our speakers included our Ambassador Natasha Stott Despoja, Chair of Ovarian Cancer Australia Paula Benson, and ovarian cancer survivor Connie Nikolovski. Guests included the Federal Minister for Health, the Hon. Tanya Plibersek, CEO of Cancer Australia, Dr Helen Zorbas, members of the Senate Committee for Community Affairs, parliamentarians, ovarian cancer consumers and key stakeholders in gynaecological cancers.

Over the past year Ovarian Cancer Australia has sent 300 copies of *Resilience* to women diagnosed. We have also created an online ordering page.

In late 2012 Ovarian Cancer Australia will launch a DVD which will provide support and information to women diagnosed and their families, designed to be a companion resource to *Resilience*.

Thanks must go to Andrea Ball from On the Ball Communications who worked with us to create the content for *Resilience* and to photographer and designer Mark Avellino for managing the design and production of the resource.
Ovarian Cancer Australia

Support Coordinators

In September 2011 Ovarian Cancer Australia employed a Support Coordinator in Perth and in April we welcomed a new Support Coordinator in Sydney. Support Co-ordinators are the local presence of the organisation: they provide support to local support groups, offer information about Ovarian Cancer Australia’s services and resources, and network with health professionals in the sector. In Perth our Support Coordinator organised an engaging and well-attended consumer forum during Ovarian Cancer Awareness Month. Gynaecological Oncologist Dr Stuart Salfinger and Gynaecological Cancer Nurse Co-ordinator Ms Pauline Tanner, both members of our Medical & Research Advisory Group, were among the guest speakers.

In 2011-12 ovarian Cancer Australia’s key support programs and resources include:

- Information & referral line – Ovarian Cancer Australia’s information, referral and support line is available from Monday to Friday from 9am to 5pm for the cost of a local call. Over the past year Ovarian Cancer Australia has received approximately 300 calls from women concerned about the symptoms of ovarian cancer and more than 350 calls requesting support and referral.

- Monthly facilitated support groups around Australia – Support groups provide an opportunity for women with ovarian cancer to discuss common issues, share stories, gain more information, and receive emotional support to help them cope with their diagnosis and treatment. We also welcome women with other gynaecological cancers. At many of our monthly support group meetings in Sydney, Melbourne, Brisbane, Perth and Darwin we provide guest speakers on a range of relevant topics including the latest ovarian cancer research, genetic testing, palliative care, managing stress, as well as complementary therapies such as massage, tai chi, and skin care. We are very grateful to all of our support group facilitators who dedicate their time and energy to the support groups including: Helen Bonyenge, Helen Gooden and Rosalind Robertson in Sydney; Rose Fraser and Klazina Zuiderma in Brisbane; Marie Smyth, Michele Librizzi and Wendy Cowell in Perth; Debbie McCabe in Melbourne and Marg Lavery in Darwin.

- Monthly telephone support group – Ovarian Cancer Australia’s monthly telephone support group, which was established with funding from Cancer Australia, is ideal for women based in rural and regional areas and women unable to travel. Over the past year Ovarian Cancer Australia’s telephone support group has covered a wide range of topics including sexuality, treatment trends, goal setting, genetic testing, hypnotherapy and clinical trials. The group is co-facilitated by our Regional Support Coordinator and Support Programs Officer who create a monthly summary of discussion. More than 50 women across Australia are registered for the group.

- Family & friends support – Being diagnosed with ovarian cancer is a difficult time not only for women diagnosed but also for family and friends. Ovarian Cancer Australia’s booklet for families, friends and carers provides advice to help them support their loved one and look after themselves. The booklet provides helpful, practical advice and includes personal insights from women living with ovarian cancer. In 2011-12 we distributed several hundred copies around Australia. Each year Ovarian Cancer Australia also hosts a family and friends day out in Melbourne where those affected by ovarian cancer have the opportunity to meet others in a similar situation.

- Online Forum – Ovarian Cancer Australia’s online forum provides a space for women to connect with one another and ask questions at any time from any location. Mostly women with ovarian cancer access this site, however there is also a space dedicated for family, friends and carers. Ovarian Cancer Australia’s online forum has more than 150 registered participants and attracts approximately 10 new participants each month.
• **Ovarian Cancer Australia and BreaCan Support Project** – The Ovarian Cancer Australia and BreaCan joint project commenced in September 2011 to improve access to information and support for women in Victoria with a gynaecological cancer. 47 women in Victoria with gynaecological cancers (the majority with ovarian cancer) engaged with the project, as well as a number of health professionals.

Over the past year we have held a number of information sessions for women diagnosed with ovarian cancer including a session in February with guest speaker Professor David Bowtell from the Australian Ovarian Cancer Study about the latest research and developments in the field. Over 50 people attended.

In June we hosted a ‘Caring for You’ session in Melbourne and in September co-hosted an event with the Royal Women’s Hospital in Melbourne with expert clinicians discussing sexuality after surgery and treatment, managing menopausal symptoms and the emotional impact of cancer.

We have also created an information sheet for women when they are diagnosed which outlines key support services, relevant information, reputable web sites and useful resources.

The findings from our project will identify referral pathways within the health sector and guide Ovarian Cancer Australia and BreaCan to ensure our services address women’s key needs both in Victoria and nationally.

**OVARIAN CANCER AUSTRALIA’S ADVOCACY WORK**

Ovarian Cancer Australia plays a leading role in providing a ‘voice’ for women diagnosed with ovarian cancer by representing their perspectives and interests, and those of their carers and supporters, to health professionals, government and the public.

In 2011-12 the board and management of Ovarian Cancer Australia participated in the following cancer working groups and forums representing the needs and interests of women with ovarian cancer:

• Cancer Australia’s Gynaecological Cancer Advisory Group
• Cancer Australia’s National Framework for Consumer Involvement in Cancer Control
• Cancer Australia’s Review of Gynaecological Cancer Consumer Fact Sheets Working Group
• Cancer Australia’s Review of Clinical Practice Guidelines – Chemotherapy for Ovarian Cancer Working Group
• Cancer Research Leadership Forum, a voluntary coalition of the major national charities funding cancer research
• Peak Cancer Consumer Reference Group, led by Cancer Council Victoria
• Australia New Zealand Gynaecological Oncology Group (ANZGOG) Consumer/Community Committee
• Attendance at Clinical Oncological Society of Australia (COSA) Annual Scientific Meeting

At a more general level Ovarian Cancer Australia ensures that the general community, including government and corporate sectors, is kept aware of the impact of ovarian cancer on women and their families through a national media campaign during Ovarian Cancer Awareness Month in February.
OVARIAN CANCER AUSTRALIA’S RESEARCH PROGRAM

In May 2012 Ovarian Cancer Australia opened applications to our new national research program – the first ever national peer-reviewed ovarian cancer research program in Australia.

Our research program was created in recognition of the poor survival rates for women diagnosed with ovarian cancer which continue to languish well below survival rates for many other cancers. The gains made in survival rates for some cancers has been in large part due to investment made in research. We know that the majority of ovarian cancer cases are diagnosed in the late stages, which is why research into treatment and diagnosis – in addition to early detection – is so critical.

Ovarian Cancer Australia’s key objective is to support and promote excellence in ovarian cancer research nationally. Through a transparent and stringent peer review process Ovarian Cancer Australia will fund research that is:

• Competitive
• Innovative
• Patient focused

In 2012 Ovarian Cancer Australia will support the brightest Australian PhD students via a competitive Postgraduate Scholarship Scheme. Ovarian Cancer Australia will award two scholarships of a total value of $75,000 each, offered as $25,000 per annum over 3 years. We aim to grow these grants significantly over the next few years.

We have appointed a national Research Committee to lead the implementation and future growth of our research program and to determine priorities for funding in consultation with our Medical & Research Advisory Group, as well as government and medical stakeholders. Our Research Committee provides a rigorous and unbiased review of all research funding applications submitted annually to Ovarian Cancer Australia, and makes recommendations on funding applications.

In 2012 our committee includes:

**Professor Ian Olver**
CEO, Cancer Council Australia

**Associate Professor Penny Webb**
Group Leader, Gynaecological Cancers Group, Queensland Institute of Medical Research

**Professor Michael Friedlander**
Professor of Medicine, University of NSW and Director of Medical Oncology, Prince of Wales Hospital, Sydney

In May 2012 Ovarian Cancer Australia co-convened a research forum for consumers with Prostate Cancer Foundation of Australia (PCFA) titled ‘Our Research, Your Future’. This one-day forum held at St Vincent’s Hospital in Melbourne was designed to provide information on prostate and ovarian cancer research results and research in progress to individuals affected by these diseases and their families and carers. The forum also provided a dynamic and stimulating environment for individuals to ask research related questions directly to researchers and a panel of experts. More than 100 people attended the forum.

A special thanks to our wonderful facilitator Julie McCrossin for engaging the audience and bringing warmth and humour to a serious topic, and to our guest speakers and panellists:

• Professor David Bowtell, Head of Cancer Genomics and Genetics at Peter MacCallum Cancer Centre
• Dr Deborah Neesham, Gynaecological Oncologist, Royal Women’s Hospital, Melbourne
• Ms Jane Fletcher, Psycho-Oncologist
• Associate Professor Brian Le, Palliative Care Physician and Medical Oncologist

At the forum we were also delighted to present an Award of Appreciation to Sylvia Penberthy who was diagnosed with ovarian cancer in 2005 and has worked tirelessly to raise awareness of ovarian cancer in her local community in NSW and funds for Ovarian Cancer Australia.
2012 Ovarian Cancer Awareness Month was bigger and better than ever before, with a range of activities and initiatives held around Australia throughout the month.

**CELEBRITY AMBASSADORS**

Our Celebrity Ambassadors play an invaluable role in helping us raise awareness of ovarian cancer in the media and the community. We were very fortunate to have such accomplished, high-profile women participate in our 2012 Ovarian Cancer Awareness Month campaign.

**Patricia Bailey**, registered nurse and sister of Crown Princess Mary of Denmark (Tasmania)

**Alice Burton**, radio and television personality (Northern Territory)

**Natasha Stott Despoja**, social commentator and former leader of the Australian Democrats (South Australia)

**Kelly O’Dwyer**, Federal Member for Higgins (Victoria)

**Meshel Laurie**, radio and television personality (Victoria)

**Jane Stephens**, pharmacist and sister of Crown Princess Mary of Denmark (Tasmania)

**Dani Venn**, MasterChef contestant and food writer (New South Wales)

**Madeleine West**, actor (Victoria)

**Haley Bracken**, media personality (New South Wales)
OUR OFFICIAL LAUNCH AT FEDERATION SQUARE, MELBOURNE

On 1 February we held our official launch of Ovarian Cancer Awareness Month at Federation Square in Melbourne with guest speakers Professor David Bowtell, Head of Cancer Genomics and Genetics at Peter MacCallum Cancer Centre, Carmel McCarthy, ovarian cancer survivor, Paula Benson, Chair of Ovarian Cancer, and MC Nicole Livingstone, Patron of Ovarian Cancer Australia. Professor Bowtell spoke about the importance of investing in research and Carmel McCarthy shared her experiences with ovarian cancer. Approximately 100 of our supporters, partners, health professionals and women diagnosed and their families attended the event.

ALFRESCO AFTERNOON TEAL, SYDNEY

On 2 February we held an ‘Alfresco Afternoon Teal’ in Wynyard Park in Sydney with our Ambassadors Patricia Bailey, Haley Bracken and Dani Venn. We had goody bags to give away to passersby with information about the signs and symptoms of ovarian cancer and holding an Afternoon Teal, as well as goodies from Moccona, Cadbury, Oreo, T2, St. George Food Services, Salad Fresh and Burgen bread. People could pick up a pack, and take a free tea or coffee from the Ovarian Cancer Australia marquee, erected for the day, in exchange for a gold coin donation. In addition our volunteers sold branded merchandise and collected donations. Despite the heavy rain it was a fantastic event!

Our presenters and MC at the launch of Ovarian Cancer Awareness Month

Some of our women at the launch of Ovarian Cancer Awareness Month

Our Ambassadors brave the weather!

Our Mrs Australia Quest volunteers

Community Ambassador Cynthia Jeong and friend volunteer (left) and supporters viewing merchandise in the marquee (right)
AFTERNOON TEAL EVENTS

We continued the success of ‘Afternoon Teal’ in 2012 with Meshel Laurie as our wonderful Afternoon Teal Ambassador. During Ovarian Cancer Awareness Month we invited our supporters and the community to host a tea with friends, family and colleagues to raise awareness of ovarian cancer amongst their networks and to raise funds for our support programs. We also held our own Afternoon Teal in the Ovarian Cancer Australia head office in Melbourne.

In total there were almost 350 Afternoon Teal events held around Australia to help fund our awareness, support and research programs.

K.I.S.S. CAMPAIGN

On Valentine’s Day Ovarian Cancer Australia launched a social media campaign to encourage women to K.I.S.S. (Know the Important Signs & Symptoms). Australians were invited to send a virtual kiss via facebook.com/OvarianCancerAustralia to all the women in their life with information about the signs and symptoms of ovarian cancer.

The campaign was a great success with hundreds of virtual kisses downloaded and sent through facebook, a number of high-profile people and organisations tweeting their followers and encouraging them to #sendakiss, and blanket online metropolitan media coverage.

K.I.S.S. is a trademark of the Ovarian Cancer National Alliance, used with permission.
LOVE NEVER DIES

On Teal Ribbon Day the Andrew Lloyd Webber production Love Never Dies dedicated their evening performance at the Capitol Theatre in Sydney to raising funds for Ovarian Cancer Australia from the sale of tickets and an audience collection. It was a thrill to see the cast, including the famous Phantom, wearing our teal ribbons for the curtain call.

MEDIA COVERAGE

During Ovarian Cancer Awareness Month Ovarian Cancer Australia generated approximately 330 pieces of media coverage.


We also had television coverage to mark Teal Ribbon Day on:

• TODAY Show, Channel 9 – live cross with Ambassadors Patricia Bailey and Jane Stephens
• The Circle, Channel 10 – in-studio interview with Ambassadors Patricia Bailey and Jane Stephens
• Mornings, Channel 9 – interview with ovarian cancer survivor Bridgette Coy

Ovarian cancer doesn’t discriminate and on Teal Ribbon Day, sparring partners Senator the Hon. Stephen Conroy, Minister for Broadband, Communications and the Digital Economy and the Hon. Malcolm Turnbull MP, Shadow Minister for Communications and Broadband, joined forces to raise awareness of the disease.
During 2011-12 Ovarian Cancer Australia received wonderful support from our corporate and community partners.

A sincere thank you to our major partners Chemmart, Nursing Australia, Minter Ellison, Showbiz, Brazilian Butterfly, Plush Sofas, Go To Wo, Keraney & Co and Curtin & Co and our corporate supporters Healthscope, Basketball Australia, Melbourne Storm, Melbourne Rebels, MPM Quality People, Woman's Day magazine, Omara Cycle Tri-It Women’s Triathlon and Mrs Australia Quest.

As well as the activities outlined below, many of our corporate partners and supporters supported us with activities throughout the year.

Thank you also to Roche and Prima BioMed for their assistance to fund our support resources.

**PARTNER ACTIVITIES**

**Chemmart Pharmacy**

Chemmart was once again a wonderful supporter of Ovarian Cancer Australia. During 2012 Awareness Month pharmacies around Australia held a range of in-store fundraising activities. Special mention must go to Eaton Chemmart, Brooks Garden Chemmart, Chemmart Woodlake Village, Rochester Chemmart, Casey Central Chemmart and Fulham Chemmart and the Tasmanian Chemmart Pharmacies who competed in Run the Bridge for going above and beyond in their efforts to raise awareness and funds.

**Showbiz**

Once again Showbiz supported Ovarian Cancer Australia through donations and facilitating ticket sales for the special Teal Ribbon Day performance of Love Never Dies.

**Brazilian Butterfly**

In 2011 Brazilian Butterfly came on board as a committed partner of Ovarian Cancer Australia, selling our merchandise in-store and raising funds and awareness through the Brazilian Butterfly Queen of the Lake fun run in Melbourne. The Ovarian Cancer Australia team participated in the event and hosted a stand.

**Nursing Australia**

Nursing Australia continued to support Ovarian Cancer Australia throughout the year by providing space for our metropolitan support group meetings and contributing to our support programs.

**Spotlight**

Spotlight stores around Australia sold our merchandise throughout February and featured Ovarian Cancer Awareness Month in their in-store publication.

[Volunteers at Brazilian Butterfly’s Queen of the Lake]

[Chemmart Pharmacies participate in Run the Bridge Tasmania]

[Brazilian Butterfly founder Tanya Farrar presented Ovarian Cancer Australia CEO Annabel Davies with a cheque from Queen of the Lake]
CORPORATE SUPPORTER ACTIVITIES

Plush Sofas supports Ovarian Cancer Australia by contributing proceeds from the sale of their ‘Snuggle’ chairs. They have even created one in teal!

Healthscope hospitals around Australia held Afternoon Teals to raise awareness and funds.

Basketball Australia held a Teal Ribbon Round in the WNBL during Ovarian Cancer Awareness Month with a televised interview with an Ovarian Cancer Australia representative.

Melbourne Storm rugby league team showed their support through hosting a ‘Women in League’ event.

Omara Cycle Tri-it Women’s Triathlon was held during Ovarian Cancer Awareness Month with all participants encouraged to fundraise for Ovarian Cancer Australia.

Logan Thunder supports Teal Ribbon Round

Our fabulous volunteers at the Omara Women’s Tri-it Triathlon

Mrs Australia Quest contestants raised funds and awareness for Ovarian Cancer Australia throughout the year.

Melbourne Rebels rugby union team showed their support with players sharing their Mother’s Day stories for our awareness campaign and a Mother’s Day charity game day.

WNBL star basketballers with Ovarian Cancer Australia Patron Nicole Livingstone

Melbourne Rebels participate in Brazilian Butterfly’s Queen of the Lake
VOLUNTEER FUNDRAISING ACTIVITIES

During 2011-12 our community of volunteers and fundraisers held a range of activities around Australia, raising considerable funds and awareness of ovarian cancer.

Events were held in small and large businesses, state, federal and local government, hospitals, clubs, associations and in backyards.

Our fundraising initiative ‘Afternoon Teal’ went from strength to strength where events ranged from simple afternoon tea at workplaces to extravagant formal affairs. Some highlights of fundraising events held during Ovarian Cancer Awareness Month included:

• King Edward Hospital in Western Australia hosted an Afternoon Teal complete with teal cupcakes
• Ovarian Cancer Australia Ambassador Alice Burton hosted a lavish cock’teal’ party in Darwin with plenty of teal dresses and accessories
• The Prime Minister’s partner Tim Mathieson hosted a Morning Teal at The Lodge
• Sing For Jenny – an event held in Bendigo in memory of Jenny, who passed away from ovarian cancer
Some highlights of fundraising events held throughout the year included:

- West Pymble Community Golf Day raised awareness of ovarian cancer in the Pymble community
- Marcus Oldham School Charity Rugby Day raised funds for ovarian cancer in memory of a student’s mother
- Year 12 students at St Michael’s School in Tasmania raised funds throughout the year in support of a teacher who had recently been diagnosed
- Peel Thunder Ladies Day raised funds through the Peel Thunder football and netball club
- Tandem Bike Ride from Kalgoorlie to Kambalda undertaken by a terrific woman diagnosed with ovarian cancer

**FUN RUNS AND MARATHONS**

From Run Melbourne to the City2Surf in Sydney we’ve received fantastic support from runners and walkers around Australia. Thank you to all who participated!
Thank you to the Victorian Department of Health for their support for our Symptom diary mobile application.

Thank you to Prima BioMed and Roche for their assistance to fund our Resilience support DVD.
Ovarian Cancer Australia is a small organisation with a big job.
If you can help us by holding an awareness and fundraising event, volunteering, making a donation, or remembering us in your will please visit www.ovariancancer.net.au or call us on 1300 660 334.
CONTENTS

Directors’ Report 3
Auditor’s Independence Declaration 5
Income Statement 6
Statement of Financial Position 7
Statement of Changes in Equity 8
Statement of Cash Flows 9
Notes to the Financial Statements 10
Directors’ Declaration 17
Independent Audit Report 18
DIRECTORS’ REPORT

Your directors present this report on the entity for the financial year ended 30 June 2012.

Directors

The names of each person who has been a director during the year and to the date of this report are:

- Simon Lee
- Karen Livingstone
- Stephanie Alvarez
- Paula Benson
- Carolyn Reynolds

Directors have been in office since the start of the financial year to the date of this report unless otherwise stated.

Company Secretary

The following person held the position of entity secretary at the end of the financial year:

Paula Benson, who was appointed Secretary on 01/07/2010.

Principal Activities

The principal activities of the organisation during the financial year were unchanged from our original mission. Ovarian Cancer Australia Limited seek to:

- Support women with ovarian cancer, their families, friends and carers with compassionate support programs and practical resources.
- Educate communities and individuals about the disease and increase the awareness of symptoms and the latest treatment, research and clinical trials from across Australia.
- Advocate to improve outcomes, treatment and quality of life for women with ovarian cancer.
- Fund innovative and world leading ovarian cancer research.

Operating Results

Ovarian Cancer Australia Limited achieved a net profit of $284,559 during the year.

Dividends Paid or Recommended

The constitution of the company prohibits the payment of dividends.

Review of Operations

The significant increase in revenue earning activities resulted in a net profit of $284,559.

After Balance Date Events

No matters or circumstances have arisen since the end of the financial year which significantly affected or may significantly affect the operations of the entity, the results of those operations, or the state of affairs of the entity in future financial years.

Future Developments

The entity expects to maintain the present status and level of operations and hence there are no likely developments in the entity’s operations.

Environmental Issues

The entity’s operations are not regulated by any significant environmental regulation under a law of the Commonwealth or of a state or territory.
Options
No options over issued shares or interests in the entity were granted during or since the end of the financial year and there were no options outstanding at the date of this report.

Meetings of Directors
During the financial year, 11 meetings of directors were held. Attendees by each director were as follows:

<table>
<thead>
<tr>
<th>Directors Meetings</th>
<th>No. eligible to attend</th>
<th>No. attended</th>
</tr>
</thead>
<tbody>
<tr>
<td>Simon Lee</td>
<td>11</td>
<td>6</td>
</tr>
<tr>
<td>Karen Livingstone</td>
<td>11</td>
<td>9</td>
</tr>
<tr>
<td>Stephanie Alvarez</td>
<td>11</td>
<td>9</td>
</tr>
<tr>
<td>Paula Benson</td>
<td>11</td>
<td>10</td>
</tr>
<tr>
<td>Carolyn Reynolds</td>
<td>11</td>
<td>11</td>
</tr>
</tbody>
</table>

Indemnifying Officers or Auditor
No indemnities have been given or insurance premiums paid, during or since the end of the financial year, for any person who is or has been an officer or auditor of the entity.

Proceedings on Behalf of the Entity
No person has applied for leave of Court to bring proceedings on behalf of the entity or intervene in any proceedings to which the entity is a party for the purpose of taking responsibility on behalf of the entity for all or any part of those proceedings.

The entity was not a party to any such proceedings during the year.

Auditor’s Independence Declaration
The lead auditor’s independence declaration for the year ended 30 June 2012 has been received and can be found on page 5 of the directors’ report.

Signed in accordance with a resolution of the Board of Directors.

Director

[Signature]
Paula Benson

Dated: 27 September 2012
Ovarian Cancer Australia Limited ABN 76 097 394 593

AUDITOR’S INDEPENDENCE DECLARATION
UNDER SECTION 307C OF THE CORPORATIONS ACT 2001
TO THE DIRECTORS OF OVARIAN CANCER AUSTRALIA LIMITED

I declare that, to the best of my knowledge and belief, during the year ended 30 June 2012 there have been

i. no contraventions of the auditor independence requirements as set out in the Corporations Act 2001 in relation to the audit; and

ii. no contraventions of any applicable code of professional conduct in relation to the audit.

Name of firm: Curtain & Co, Chartered Accountants
Name of partner: Peter Gillis
Signature:

Date: 27 September 2012
Address: 5th Floor
369 Royal Parade
Parkville VIC 3052
## OVARIAN CANCER AUSTRALIA LIMITED
### INCOME STATEMENT FOR THE YEAR ENDED 30 JUNE 2012

<table>
<thead>
<tr>
<th>Note</th>
<th>2012</th>
<th>2011</th>
</tr>
</thead>
<tbody>
<tr>
<td>Revenue</td>
<td>1,230,812</td>
<td>849,625</td>
</tr>
<tr>
<td>Interest Income</td>
<td>18,734</td>
<td>126</td>
</tr>
<tr>
<td>Loss on sale of plant and equipment</td>
<td>-</td>
<td>(110)</td>
</tr>
<tr>
<td>Cost of goods sold</td>
<td>(154,770)</td>
<td>(66,305)</td>
</tr>
<tr>
<td>Marketing / awareness expenses</td>
<td>(185,926)</td>
<td>(140,227)</td>
</tr>
<tr>
<td>Premises rent &amp; venue/equipment hire</td>
<td>(20,938)</td>
<td>(29,593)</td>
</tr>
<tr>
<td>Depreciation and amortisation expenses</td>
<td>(14,353)</td>
<td>(15,545)</td>
</tr>
<tr>
<td>Employment expenses</td>
<td>(345,202)</td>
<td>(253,262)</td>
</tr>
<tr>
<td>Administrative expenses</td>
<td>(243,798)</td>
<td>(149,190)</td>
</tr>
<tr>
<td><strong>Profit before income tax</strong></td>
<td>2</td>
<td>2</td>
</tr>
<tr>
<td><strong>Revenue</strong></td>
<td>284,559</td>
<td>195,519</td>
</tr>
<tr>
<td><strong>Interest Income</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Cost of goods sold</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Marketing / awareness expenses</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Premises rent &amp; venue/equipment hire</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Depreciation and amortisation expenses</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Employment expenses</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Administrative expenses</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Profit before income tax</strong></td>
<td>2</td>
<td>2</td>
</tr>
<tr>
<td><strong>Income tax expense</strong></td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td><strong>Profit after income tax</strong></td>
<td>284,559</td>
<td>195,519</td>
</tr>
</tbody>
</table>

The accompanying notes form part of these financial statements.
Ovarian Cancer Australia Limited ABN 76 097 394 593

OVARIAN CANCER AUSTRALIA LIMITED
STATEMENT OF FINANCIAL POSITION AS AT 30 JUNE 2012

<table>
<thead>
<tr>
<th>Note</th>
<th>2012</th>
<th>2011</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>$</td>
<td>$</td>
</tr>
<tr>
<td><strong>ASSETS</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>CURRENT ASSETS</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cash and cash equivalents</td>
<td>3</td>
<td>909,369</td>
</tr>
<tr>
<td>Trade and other receivables</td>
<td>4</td>
<td>29,264</td>
</tr>
<tr>
<td>Inventories</td>
<td>5</td>
<td>2,460</td>
</tr>
<tr>
<td>Other assets</td>
<td>6</td>
<td>51,634</td>
</tr>
<tr>
<td><strong>TOTAL CURRENT ASSETS</strong></td>
<td></td>
<td>992,727</td>
</tr>
<tr>
<td><strong>NON-CURRENT ASSETS</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Plant and equipment</td>
<td>7</td>
<td>14,719</td>
</tr>
<tr>
<td>Intangible assets</td>
<td>8</td>
<td>27,670</td>
</tr>
<tr>
<td><strong>TOTAL NON-CURRENT ASSETS</strong></td>
<td></td>
<td>42,389</td>
</tr>
<tr>
<td><strong>TOTAL ASSETS</strong></td>
<td></td>
<td>1,035,116</td>
</tr>
<tr>
<td><strong>CURRENT LIABILITIES</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Trade and other payables</td>
<td>9</td>
<td>87,064</td>
</tr>
<tr>
<td>Provisions</td>
<td>9</td>
<td>18,423</td>
</tr>
<tr>
<td>Other current liabilities</td>
<td>9</td>
<td>12,284</td>
</tr>
<tr>
<td><strong>TOTAL CURRENT LIABILITIES</strong></td>
<td></td>
<td>117,771</td>
</tr>
<tr>
<td><strong>TOTAL LIABILITIES</strong></td>
<td></td>
<td>117,771</td>
</tr>
<tr>
<td><strong>NET ASSETS</strong></td>
<td></td>
<td>917,345</td>
</tr>
<tr>
<td><strong>EQUITY</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Settled sum</td>
<td></td>
<td>200</td>
</tr>
<tr>
<td>Retained earnings</td>
<td></td>
<td>917,145</td>
</tr>
<tr>
<td><strong>TOTAL EQUITY</strong></td>
<td></td>
<td>917,345</td>
</tr>
</tbody>
</table>

The accompanying notes form part of these financial statements.
Ovarian Cancer Australia Limited ABN 76 097 394 593

OVARIAN CANCER AUSTRALIA LIMITED
STATEMENT OF CHANGES IN EQUITY
FOR THE YEAR ENDED 30 JUNE 2012

<table>
<thead>
<tr>
<th></th>
<th>Settled Sum</th>
<th>Retained Earnings</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Balance at 30 June 2010</strong></td>
<td>200</td>
<td>437,067</td>
<td>437,267</td>
</tr>
<tr>
<td>Profit attributable to the entity</td>
<td>-</td>
<td>195,519</td>
<td>195,519</td>
</tr>
<tr>
<td><strong>Balance at 30 June 2011</strong></td>
<td>200</td>
<td>632,586</td>
<td>632,786</td>
</tr>
<tr>
<td>Profit attributable to the entity</td>
<td>-</td>
<td>284,559</td>
<td>284,559</td>
</tr>
<tr>
<td><strong>Balance at 30 June 2012</strong></td>
<td>200</td>
<td>917,145</td>
<td>917,345</td>
</tr>
</tbody>
</table>

The accompanying notes form part of these financial statements.
## Ovarian Cancer Australia Limited ABN 76 097 394 593

### Ovarian Cancer Australia Limited

#### STATEMENT OF CASH FLOWS FOR THE YEAR ENDED 30 JUNE 2012

<table>
<thead>
<tr>
<th>Note</th>
<th>2012 $</th>
<th>2011 $</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>CASH FLOW FROM OPERATING ACTIVITIES</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Receipts from customers</td>
<td>1,154,953</td>
<td>871,120</td>
</tr>
<tr>
<td>Payments to suppliers and employees</td>
<td>(903,846)</td>
<td>(593,120)</td>
</tr>
<tr>
<td>Interest received</td>
<td>18,734</td>
<td>126</td>
</tr>
<tr>
<td><strong>Net cash generated from operating activities</strong></td>
<td>269,841</td>
<td>278,126</td>
</tr>
<tr>
<td><strong>CASH FLOW FROM INVESTING ACTIVITIES</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Purchase of fixed assets</td>
<td>(9,655)</td>
<td>(24,715)</td>
</tr>
<tr>
<td><strong>Net cash used in investing activities</strong></td>
<td>(9,655)</td>
<td>(24,715)</td>
</tr>
<tr>
<td>Net increase in cash held</td>
<td>260,186</td>
<td>253,411</td>
</tr>
<tr>
<td>Cash at the beginning of the financial year</td>
<td>649,183</td>
<td>395,772</td>
</tr>
<tr>
<td><strong>Cash at the end of the financial year</strong></td>
<td>909,369</td>
<td>649,183</td>
</tr>
</tbody>
</table>

The accompanying notes form part of these financial statements.
NOTE 1: STATEMENT OF SIGNIFICANT ACCOUNTING POLICIES

The financial report is a special purpose financial report that has been prepared in accordance with the

The financial report is for Ovarian Cancer Australia Limited as an individual entity, incorporated and
domiciled in Australia.

Basis of Preparation

The report has been prepared in accordance with the requirements of the Corporations Act 2001, and the
following applicable Australian Accounting Standards and Australian Accounting Interpretations.

- AASB 101: Presentation of Financial Statements;
- AASB 107: Cash Flow Statements;
- AASB 108: Accounting Policies, Changes in Accounting Estimates and Errors;
- AASB 110: Events after the Balance Sheet Date;
- AASB 1004: Contributions;
- AASB 1031: Materiality; and
- AASB 1048: Interpretation and Application of Standards.

No other Accounting Standards, Accounting Interpretations or other authoritative pronouncements of the
Australian Accounting Standards Board have been applied.

Reporting Basis and Conversions

The financial report has been prepared on an accruals basis and is based on historical costs. It does not
take into account changing money values or, except where stated, current valuations of non current
assets. Cost is based on the fair values of the consideration given in exchange for assets.

The following is a summary of the material accounting policies adopted by the entity in the preparation of
the financial report. The accounting policies have been consistently applied, unless otherwise stated.

Accounting Policies

a. Revenue

Revenue from the sale of goods is recognised upon the delivery of goods to customers.
Grant revenue is recognised in the income statement when it is controlled. When there are
conditions attached to grant revenue relating to the use of those grants for specific purposes it is
recognised in the balance sheet as a liability until such conditions are met or services provided.
Donations and bequests are recognised as revenue when received unless they are designated for
a specific purpose, where they are carried forward as prepaid income on the balance sheet.
Interest revenue and distribution income from investments is recognised on a proportional basis
taking into account the interest rates applicable to the financial assets.
Revenue from the rendering of a service is recognised upon the delivery of the service to the
customers.
All revenue is stated net of the amount of goods and services tax (GST).

b. Inventories

Inventories are measured at the lower of cost and current replacement cost.
Inventories acquired at no cost, or for nominal consideration are valued at the current replacement
cost as at the date of acquisition.

c. Plant and Equipment

Each class of plant and equipment is carried at cost or fair values less, where applicable,
accumulated depreciation and impairment losses.

Plant and equipment are measured on the cost basis less depreciation and impairment losses.
NOTE 1: STATEMENT OF SIGNIFICANT ACCOUNTING POLICIES

The carrying amount of plant and equipment is reviewed annually by directors to ensure it is not in excess of the recoverable amount from these assets. The recoverable amount is assessed on the basis of the expected net cash flows that will be received from the assets employment and subsequent disposal. The expected net cash flows have been discounted to their present values in determining recoverable amounts.

Plant and equipment that have been contributed at no cost, or for nominal cost are valued at the fair value of the asset at the date it is acquired.

Increases in the carrying amount arising on revaluation of land and buildings are credited to a revaluation reserve in equity. Decreases that offset previous increases of the same class of asset are charged against fair value reserves directly in equity; all other decreases are charged to the income statement. Each year the difference between depreciation based on the revalued carrying amount of the asset charged to the income statement and depreciation based on the asset’s original cost is transferred from the revaluation reserve to retained earnings.

Depreciation

The depreciable amount of all fixed assets is depreciated on a diminishing value basis over their useful lives to the economic entity commencing from the time the asset is held ready for use.

The assets’ residual values and useful lives are reviewed, and adjusted if appropriate, at each balance sheet date.

An asset’s carrying amount is written down immediately to its recoverable amount if the asset’s carrying amount is greater than its estimated recoverable amount.

Gains and losses on disposals are determined by comparing proceeds with the carrying amount. These gains or losses are included in the income statement. When revalued assets are sold, amounts included in the revaluation reserve relating to that asset are transferred to retained earnings.

d. Impairment of Assets

At each reporting date, the entity reviews the carrying values of its tangible and intangible assets to determine whether there is any indication that those assets have been impaired. If such an indication exists, the recoverable amount of the asset, being the higher of the asset’s fair value less costs to sell and value in use, is compared to the asset’s carrying value. Any excess of the asset’s carrying value over its recoverable amount is expensed to the Income Statement.

Where the future economic benefits of the asset are not primarily dependent upon the asset’s ability to generate net cash inflows and when the entity would, if deprived of the asset, replace its remaining future economic benefits, value in use is depreciated replacement cost of an asset.

Where it is not possible to estimate the recoverable amount of a class of asset, the entity estimates the recoverable amount of the cash-generating unit to which the asset belongs.

e. Employee Benefits

Provision is made for the entity’s liability for employee benefits arising from services rendered by employees to Balance Sheet date. Employee benefits expected to be settled within one year together with benefits arising from wages, salaries and annual leave which may be settled after one year, have been measured at the amounts expected to be paid when the liability is settled plus related on costs. Other employee benefits payable later than one year have been measured at the net present value.

Contributions are made by the entity to an employee superannuation fund and are charged as expenses when incurred.

f. Cash and cash equivalents

Cash and cash equivalents include cash on hand, deposits held at-call with banks, other short-term highly liquid investments with original maturities of three months or less, and bank overdrafts.
NOTE 1: STATEMENT OF SIGNIFICANT ACCOUNTING POLICIES

(Continued)

g. Goods and Services Tax (GST)
Revenues, expenses and assets are recognised net of the amount of GST, except where the amount of GST incurred is not recoverable from the Australian Taxation Office. In these circumstances the GST is recognised as part of the cost of acquisition of the asset or as part of an item of expense. Receivables and payables in the Balance Sheet are shown inclusive of GST.

Cash flows are presented in the Cashflow Statement on a gross basis, except for the GST component of investing and financing activities, which are disclosed as operating cash flows.

h. Unexpended Grants
The entity receives grant monies to fund projects either for contracted periods of time or for specific projects irrespective of the period of time required to complete those projects. It is the policy of the entity to treat grants monies as unexpended grants in the balance sheet where the entity is contractually obliged to provide the services in a subsequent financial period to when the grant is received or in the case of specific project grants where the project has not been completed.

i. Contributions
Ovarian Cancer Australia Limited (Non-reporting) receives non-reciprocal contributions from the government and other parties for no or a nominal value, these contributions are recognised at the fair value on the date of acquisition upon which time an asset is taken up in the balance sheet and revenue in the income statement.

j. Income Tax
No provision for income tax has been raised, as the entity is exempt from income tax under Division 50 of the *Income Tax Assessment Act 1997*.

k. Provisions
Provisions are recognised when the entity has a legal or constructive obligation, as a result of past events, for which it is probable that an outflow of economic benefits will result and that outflow can be reliably measured.

l. Comparative Figures
Where required by Accounting Standards comparative figures have been adjusted to conform with changes in presentation for the current financial year.

m. Critical Accounting Estimates and Judgments
The directors evaluate estimates and judgments incorporated into the financial report based on historical knowledge and best available current information. Estimates assume a reasonable expectation of future events and are based on current trends and economic data, obtained both externally and within the group.

The financial report was authorised for issue on 21 September 2012 by the board of directors.
NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 30 JUNE 2012

NOTE 2: PROFIT

2012 2011

$  $  

a. Expenses

Depreciation and amortisation (14,353) (15,545)
Rent – premises (20,729) (17,654)
Rent – venues / plant & equipment (209) (11,938)

b. Significant Revenue

The following significant revenue items are relevant in explaining the financial performance:

Donations 586,073 497,663
Sponsorships 150,103 77,651
Other receipts from fundraising activities 494,636 274,310

NOTE 3: CASH AND CASH EQUIVALENTS

2012 2011

$  $  

Cash at bank 909,146 649,038
Cash on hand 223 145

Reconciliation of cash

Cash and cash equivalents 909,369 649,183

NOTE 4: TRADE AND OTHER RECEIVABLES

2012 2011

$  $  

CURRENT

Trade receivables 15,382 10,084
Other receivables 13,882 8,062

29,264 18,146
### NOTE 5: INVENTORIES

<table>
<thead>
<tr>
<th></th>
<th>2012</th>
<th>2011</th>
</tr>
</thead>
<tbody>
<tr>
<td>CURRENT</td>
<td></td>
<td></td>
</tr>
<tr>
<td>At cost</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Stock</td>
<td>2,460</td>
<td>12,200</td>
</tr>
<tr>
<td>Current inventories</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### NOTE 6: OTHER ASSETS

<table>
<thead>
<tr>
<th></th>
<th>2012</th>
<th>2011</th>
</tr>
</thead>
<tbody>
<tr>
<td>CURRENT</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Rental bond(s)</td>
<td>3,050</td>
<td>2,850</td>
</tr>
<tr>
<td>Prepayments</td>
<td>11,721</td>
<td>5,356</td>
</tr>
<tr>
<td>Deposits paid</td>
<td>-</td>
<td>2,727</td>
</tr>
<tr>
<td>Accrued revenue</td>
<td>36,863</td>
<td>39,944</td>
</tr>
<tr>
<td>Credit card</td>
<td>-</td>
<td>1,926</td>
</tr>
<tr>
<td>Total current assets</td>
<td>51,634</td>
<td>52,803</td>
</tr>
</tbody>
</table>

### NOTE 7: PLANT AND EQUIPMENT

<table>
<thead>
<tr>
<th></th>
<th>2012</th>
<th>2011</th>
</tr>
</thead>
<tbody>
<tr>
<td>PLANT AND EQUIPMENT</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Plant and equipment</td>
<td></td>
<td></td>
</tr>
<tr>
<td>At cost</td>
<td>44,418</td>
<td>47,609</td>
</tr>
<tr>
<td>Less accumulated depreciation</td>
<td>(29,699)</td>
<td>(29,199)</td>
</tr>
<tr>
<td>Total plant and equipment</td>
<td>14,719</td>
<td>18,410</td>
</tr>
</tbody>
</table>

### NOTE 8: INTANGIBLE ASSETS

<table>
<thead>
<tr>
<th></th>
<th>2012</th>
<th>2011</th>
</tr>
</thead>
<tbody>
<tr>
<td>INTANGIBLE ASSETS</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Patents and trademarks</td>
<td></td>
<td></td>
</tr>
<tr>
<td>At cost</td>
<td>11,663</td>
<td>5,393</td>
</tr>
<tr>
<td>Less accumulated amortisation</td>
<td>(812)</td>
<td>(471)</td>
</tr>
<tr>
<td>Intangible assets</td>
<td></td>
<td></td>
</tr>
<tr>
<td>At cost</td>
<td>34,680</td>
<td>34,680</td>
</tr>
<tr>
<td>Less accumulated amortisation</td>
<td>(17,861)</td>
<td>(10,925)</td>
</tr>
<tr>
<td>Total intangible assets</td>
<td>27,670</td>
<td>28,677</td>
</tr>
</tbody>
</table>
NOTE 9: CURRENT LIABILITIES

<table>
<thead>
<tr>
<th></th>
<th>2012</th>
<th>2011</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>CURRENT</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Trade and other payables</td>
<td>87,064</td>
<td>53,533</td>
</tr>
<tr>
<td>Provisions</td>
<td>18,423</td>
<td>10,498</td>
</tr>
<tr>
<td>Other current liabilities</td>
<td>12,284</td>
<td>82,602</td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td>117,771</td>
<td>146,633</td>
</tr>
</tbody>
</table>

NOTE 10: EVENTS AFTER THE BALANCE DATE
No matters or circumstances have arisen since the end of the financial year which significantly affected or may significantly affect the operations of the entity, the results of those operations, or the state of affairs of the entity in future financial years.

NOTE 11: CASH FLOW INFORMATION

<table>
<thead>
<tr>
<th></th>
<th>2012</th>
<th>2011</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Reconciliation of cash flow from operations with profit after income tax</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Profit after income tax</td>
<td>284,559</td>
<td>195,519</td>
</tr>
<tr>
<td>Non cash flows in profit</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Depreciation and amortisation</td>
<td>14,353</td>
<td>15,545</td>
</tr>
<tr>
<td>Net loss on sale / write off of plant and equipment</td>
<td>-</td>
<td>110</td>
</tr>
<tr>
<td>Changes in assets and liabilities</td>
<td></td>
<td></td>
</tr>
<tr>
<td>(Increase) in receivables and other assets</td>
<td>(11,875)</td>
<td>(47,411)</td>
</tr>
<tr>
<td>Decrease in inventories</td>
<td>9,740</td>
<td>17,480</td>
</tr>
<tr>
<td>(Decrease)/Increase in other current liabilities</td>
<td>(70,318)</td>
<td>60,808</td>
</tr>
<tr>
<td>Increase in provisions</td>
<td>7,925</td>
<td>8,562</td>
</tr>
<tr>
<td>Increase in trade and other payables</td>
<td>35,457</td>
<td>27,513</td>
</tr>
<tr>
<td><strong>Cash flows provided by operating activities</strong></td>
<td>269,841</td>
<td>278,126</td>
</tr>
</tbody>
</table>
NOTE 12: OPERATING LEASE COMMITMENTS

<table>
<thead>
<tr>
<th>Commitment</th>
<th>2012</th>
<th>2011</th>
</tr>
</thead>
<tbody>
<tr>
<td>Operating Lease Commitments being for rent of office space:</td>
<td></td>
<td></td>
</tr>
<tr>
<td>- Not later than 1 year</td>
<td>26,956</td>
<td>24,265</td>
</tr>
<tr>
<td>- Later than 1 year but not later than 5 years</td>
<td>2,246</td>
<td>30,331</td>
</tr>
<tr>
<td>- Later than 5 years</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td></td>
<td>29,202</td>
<td>54,596</td>
</tr>
</tbody>
</table>

The Company moved premises from Level 2 to Level 1 during the year and entered into a new 1 year, 3 month sublease on 2nd April 2012, with annual rental of $21,304 plus GST per annum (CPI increase annually). The Company also rents out a small office space on Level 1 for $5,652 plus GST per annum (CPI increase annually).

NOTE 13: DETAILS OF COMPANY

The principal place of business of the company is:
Level 1
210 Lonsdale Street
Melbourne  VIC  3000

Its principal activity is to:-

- Support women with ovarian cancer, their families, friends and carers with compassionate support programs and practical resources.
- Educate communities and individuals about the disease and increase the awareness of symptoms and the latest treatment, research and clinical trials from across Australia.
- Advocate to improve outcomes, treatment and quality of life for women with ovarian cancer.
- Fund innovative and world leading ovarian cancer research.

NOTE 14: ENTITY DETAILS

The registered office of the company is:
Kearney and Co
Suite 8, 651 Victoria Street
Abbotsford  VIC  3067

The principal place of business is:
Ovarian Cancer Australia Limited
Level 1
210 Lonsdale Street
Melbourne  VIC  3000
Ovarian Cancer Australia Limited ABN 76 097 394 593

DIRECTORS’ DECLARATION

The Directors have determined that the Company is not a reporting entity. The Directors have determined that this special purpose financial report should be prepared in accordance with the accounting policies outlined in Note 1 to the financial statements.

The directors of the company declare that:

A. The financial statements and notes, as set out on pages 6 to 16, are in accordance with the Corporations Act 2001 and:
   i. comply with Accounting Standards; and
   ii. give a true and fair view of the financial position as at 30 June 2012 and of the performance for the year ended on that date in accordance with the accounting policies described in Note 1 of the financial statements.

B. In the directors’ opinion there are reasonable grounds to believe that the company will be able to pay its debts as and when they become due and payable.

This declaration is made in accordance with a resolution of the Board of Directors.

Paula Benson (Director)
Dated: 27 September 2012
We have audited the accompanying financial report, being a special purpose financial report, of Ovarian Cancer Australia Limited (the company), which comprises the statement of financial position as at 30 June 2012, the income statement, statement of changes in equity and statement of cash flows for the year then ended, notes comprising a summary of significant accounting policies and other explanatory information, and the Directors’ declaration.

Directors’ Responsibility for the Financial Report
The Directors of the company are responsible for the preparation of the financial report and have determined on that basis of preparation described in Note 1 is appropriate to meet the requirements of the Corporations Act 2001 and is appropriate to meet the needs of the members. The Directors’ responsibility also includes such internal control as the Directors determine is necessary to enable the preparation of a financial report that is free from material misstatement, whether due to fraud or error.

Auditor’s Responsibility
Our responsibility is to express an opinion on the financial report based on our audit. We conducted our audit in accordance with Australian Auditing Standards. These Auditing Standards require that we comply with relevant ethical requirements relating to audit engagements and plan and perform the audit to obtain reasonable assurance whether the financial report is free from material misstatement.
An audit involves performing procedures to obtain audit evidence about the amounts and disclosures in the financial report. The procedures selected depend on the auditor’s judgment, including the assessment of the risks of material misstatement of the financial report, whether due to fraud or error. In making those risk assessments, the auditor considers internal control relevant to the company’s preparation of the financial report that gives a true and fair view, in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the company’s internal control. An audit also includes evaluating the appropriateness of accounting policies used and the reasonableness of accounting estimates made by the Directors, as well as evaluating the overall presentation of the financial report.
We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.

Independence
In conducting our audit, we have complied with the independence requirements of the Corporations Act 2001. We confirm that the independence declaration required by the Corporations Act 2001, which has been given to the Directors of Ovarian Cancer Australia Limited, would be in the terms if given to the Directors as at the date of this auditor’s report.

Basis of Accounting
Without modifying our opinion, we draw attention to Note 1 to the financial report, which describes the basis of accounting. The financial report has been prepared for the purpose of fulfilling the Directors’ financial reporting responsibilities under the Corporations Act 2001. As a result, the financial report may not be suitable for another purpose.
Ovarian Cancer Australia Limited ABN 76 097 394 593

Auditor’s Opinion

In our opinion the financial report of Ovarian Cancer Australia Limited is in accordance with the Corporations Act 2001, including:

i. giving a true and fair view of the company’s financial position as at 30 June 2012 and of its performance for the year ended on that date; and

ii. complying with Australian Accounting Standards to the extent described in Note 1 and complying with the Corporations Act 2001.

Name of firm: Curtain & Co, Chartered Accountants

Name of partner: Peter Gillis

Signature:

Dated: 27 September 2012

Address: 5th Floor
369 Royal Parade
Parkville VIC 3052